{
    "nct_id": "NCT04907539",
    "official_title": "A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination With Nivolumab, in Patients With Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer Who Have Progressed Following Therapy With Current Standard of Care (PORCUPINE)",
    "inclusion_criteria": "* Histological documentation of metastatic (Stage IV) Colorectal cancer (CRC) and\n\n  1. Documented tumour tissue aberration in RNF43 and/or RSPO\n  2. Documented confirmation of microsatellite stable (MSS) status\n* Patients must have had documented radiological progression following a minimum of 1 prior SOC treatment regimen for metastatic disease\n* Eastern Cooperative Oncology Group performance status 0 or 1\n* At least one lesion that is measurable by RECIST 1.1 at baseline\n* Patients must have at least one lesion suitable for biopsy at screening and be willing to provide mandatory tumour biopsy samples\n* Patients with adequate organ functions\n* Female patients of childbearing potential must have a negative pregnancy test prior to start of dosing\n* Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 5 months after the last dose of study drug.\n\nFor patients on RXC004 monotherapy treatment (Arm A) the following inclusion criteria will also apply to enter the RXC004 + nivolumab treatment phase:\n\n* Patients must have had documented RECIST1.1 defined radiological progression on RXC004 monotherapy treatment on the first scheduled scan (week 8 +/- 1 week)\n* Patients must receive Cycle 1 Day 1 of combination study treatment within 28 days of the first scheduled scan (week 8 +/- 1 week).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with a compound of the same mechanism of action as RXC004\n* Patients at higher risk of bone fractures\n* Any known uncontrolled inter-current illness or persistent clinically significant toxicity related to prior anti-cancer treatment\n* Patients who have any history of an active (requiring treatment) other malignancy within 2 years of study entry\n* Patients with known or suspected brain metastases\n* Use of anti-neoplastic agents, immunosuppressants and other investigational drugs\n* Patients with a known hypersensitivity to any RXC004 excipients\n* Patients with a contra-indication for denosumab treatment\n* Patients who are pregnant or breast-feeding\n* Use of any live or live-attenuated vaccines against infectious diseases (e.g., influenza nasal spray, varicella) within 4 weeks (28 days) of initiation of study treatment\n* Patients with a mean resting corrected QTcF >470 ms, obtained from triplicate electrocardiograms performed at screening\n\nFor patients on RXC004 + nivolumab combination treatment (Arm B or Arm A RXC004 + nivolumab treatment phase):\n\n* Patients with any contraindication to the use of nivolumab\n* Patients with active or prior documented autoimmune or inflammatory disorders within the past 5 years\n* Patients with active infections, including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus\n* Patients with a history of allogeneic organ transplant or active primary immunodeficiency\n* Patients with a known hypersensitivity to nivolumab or any of the excipients of the product",
    "miscellaneous_criteria": ""
}